Back to Library

Johnson & Johnson

Discover What IMAAVY Can Do for Your gMG Journey

Written by
Johnson & Johnson logoJohnson & Johnson
• Published August 22, 2026 • Updated August 22, 2026 Sponsored Content
Discover What IMAAVY Can Do for Your gMG Journey

Johnson & Johnson creative content

With IMAAVY® (nipocalimab-aahu) disease control can last*

As measured by improvement in daily function using the MG-ADL scale in a 24-week clinical study

*MG-ADL improved on average by 4.7 points with IMAAVY + current gMG treatment and 3.3 points with placebo + current gMG treatment from baseline to Weeks 22, 23, and 24.

AChR=acetylcholine receptor; MG-ADL=Myasthenia Gravis Activities of Daily Living;
MuSK=muscle-specific tyrosine kinase.

Achieve significant improvement in daily function† and muscle weakness‡

 

IMAAVY + current gMG treatment§:

4.7

average point improvement

in MG-ADL score†

Patients taking placebo + current gMG treatment experienced a 3.3-point improvement on average

Items in the MG-ADL scale include:

  • Talking
  • Chewing
  • Swallowing
  • Breathing
  • Brushing teeth or hair
  • Rising from chair
  • Double vision
  • Eyelid droop

This was measured using results averaged from Weeks 22, 23, and 24 of the study compared to baseline.

 

IMAAVY + current gMG treatment§:

4.9

average point improvement

in QMG score‡

Patients taking placebo + current gMG treatment experienced a 2.1-point improvement on average

Items in the QMG scale include:

  • Double vision and upper eyelid droop
  • Ability to drink water
  • Counting out loud
  • Grip strength
  • Face and neck muscle strength
  • Breathing capacity
  • Arm strength
  • Leg strength

This was measured using results averaged from Weeks 22 and 24 of the study compared to baseline.


†Measured using the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG.

‡Measured using the Quantitative Myasthenia Gravis (QMG) scale, which assesses muscle weakness based on 13 items.

§In the study, patients were given IMAAVY + their current gMG treatment or placebo + their current gMG treatment. Current therapies included acetylcholinesterase inhibitors (85%), steroids (66%), or non-steroidal immunosuppressive therapies (54%), taken together or separately.


See the results

"I’m back to being able to do some MG activities of daily living independently now."

Allison, IMAAVY patient

Allison is a paid spokeswoman for J&J. She was not a clinical trial participant for IMAAVY. In consideration of the time Allison spent participating in this activity, she was paid honoraria by Johnson & Johnson.


Get personalized support tailored
to your unique needs

Once you and your healthcare provider have decided that IMAAVY is
 right for you, IMAAVY withMe is here for you and your loved ones with
free personalized support when and where you may need it.

Get Started





IMPORTANT SAFETY INFORMATION

WHAT IS IMAAVY® (nipocalimab-aahu)?

IMAAVY® is a prescription medicine used to treat adults and children 12 years of age and older with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

It is not known if IMAAVY® is safe and effective in children under 12 years of age.

What is the most important information I should know about IMAAVY®?

IMAAVY® is a prescription medicine that may cause serious side effects, including:

  • Infections are a common side effect of IMAAVY® that can be serious. Receiving IMAAVY® may increase your risk of infection. Tell your healthcare provider right away if you have any of the following infection symptoms:
  • fever
  • chills
  • shivering
  • cough
  • sore throat
  • fever blisters
  • burning when you urinate
  • Allergic (hypersensitivity) reactions may happen during or up to a few weeks after your IMAAVY® infusion. Get emergency medical help right away if you get any of these symptoms during or after your IMAAVY® infusion:
  • a swollen face, lips, mouth, tongue, or throat
  • difficulty swallowing or breathing
  • itchy rash (hives)
  • chest pain or tightness
  • Infusion-related reactions are possible. Tell your healthcare provider right away if you get any of these symptoms during or a few days after your IMAAVY® infusion:
  • headache
  • rash
  • nausea
  • fatigue
  • dizziness
  • chills
  • flu-like symptoms
  • redness of skin

Do not receive IMAAVY® if you have a severe allergic reaction to nipocalimab-aahu or any of the ingredients in IMAAVY®. Reactions have included angioedema and anaphylaxis.

Before using IMAAVY®, tell your healthcare provider about all of your medical conditions, including if you:

  • ever had an allergic reaction to IMAAVY®.
  • have or had any recent infections or symptoms of infection.
  • have recently received or are scheduled to receive an immunization (vaccine). People who take IMAAVY® should not receive live vaccines.
  • are pregnant, plan to become pregnant, or are breastfeeding. It is not known whether IMAAVY® will harm your baby.

Pregnancy Safety Study. There is a pregnancy safety study for IMAAVY® if IMAAVY® is given during pregnancy or you become pregnant while receiving IMAAVY®. Your healthcare provider should report IMAAVY® exposure by contacting Janssen at 1-800-526-7736 or www.IMAAVY.com.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of IMAAVY®?

IMAAVY® may cause serious side effects. See “What is the most important information I should know about IMAAVY®?”

The most common side effects of IMAAVY® include: respiratory tract infection, peripheral edema (swelling in your hands, ankles, or feet), and muscle spasms.

These are not all the possible side effects of IMAAVY®. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the full Prescribing Information and Medication Guide for IMAAVY® and discuss any questions you have with your doctor.

Dosage Form and Strengths: IMAAVY® is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.

cp-509746v1